Aims/hypothesis Adipose tissue is a highly versatile system in which mitochondria in adipocytes undergo significant changes during active tissue remodelling. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a mitochondrial protein and a known mitochondrial quality regulator. In this study, we investigated the role of BNIP3 in adipocytes, specifically under conditions of peroxisome proliferator-activated receptor-γ (PPARγ)-induced adipose tissue remodelling. Methods The expression of BNIP3 was evaluated in 3T3-L1 adipocytes in vitro, C57BL/6 mice fed a high-fat diet and db/db mice in vivo. Mitochondrial bioenergetics was investigated in BNIP3-knockdown adipocytes after rosiglitazone treatment. A putative peroxisome proliferator hormone responsive element (PPRE) was characterised by promoter assay and electrophoretic mobility shift assay (EMSA).
Introduction
Adipocytes are one of the cell types that remodel dynamically in number and size [1] . Within adipocytes, mitochondria show robust changes in density and morphology under pathophysiological conditions [2, 3] . Excess mitochondria occur with myopathy or cancer [4] and reduced mitochondria number and/or function is associated with obesity [5] [6] [7] . This suggests that tight quality control of the mitochondria may be critical for maintaining adipocyte function during adipocyte remodelling.
Peroxisome proliferator-activated receptor-γ (PPARγ) is a key transcription factor essential for adipocyte differentiation [8] . Agonists of PPARγ improve insulin resistance, probably by stimulating the storage of excess energy as fat, thus improving blood glucose [9] . Many studies have also reported that PPARγ agonists induce mitochondrial biogenesis [2, 7, 10, 11] . Based on the critical role of mitochondria in energy generation, mitochondrial biogenesis may contribute to PPARγ-agonist-induced improvement in insulin resistance [12] . However, the molecular mechanisms of impaired mitochondrial function and restoration of mitochondrial bioenergetics by PPARγ agonists in obesity are still poorly understood.
Located at the outer membrane of mitochondria, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) was originally known as an inducer of apoptosis [13] . Additionally, BNIP3 is also an inducer of autophagyrelated cell survival [14] . Under certain stress conditions, such as hypoxia, BNIP3 controls mitochondrial quality by removing damaged mitochondria via autophagy/mitophagy, and protects cells from death [15] . This bidirectional action of BNIP3 between apoptosis and autophagy suggests that BNIP3 may be a key regulator of cell fate between cell death and survival during dynamic remodelling [16, 17] .
The biological significance of BNIP3 has been investigated largely in myocytes and cancer cells [18, 19] , cell types in which mitochondria are abundant. In terms of other metabolism-related effects in tissues, a group has reported that BNIP3-null mice livers have higher mitochondrial mass but impaired function compared with control mice [20] . Another study has shown that Bnip3 transcription is upregulated during brown fat adipogenesis [21] . However, the role of BNIP3 in white adipose tissue (WAT), a mitochondria-poor tissue, has not been evaluated. Considering that a PPARγ agonist induces robust mitochondria biogenesis in adipocytes, we hypothesised that BNIP3 influences adipose tissue remodelling by regulating mitochondrial bioenergetics under rosiglitazone-treated conditions.
Methods
Animal experiments We used C57BLKS/J diabetic Lepr (db/db) and lean control (db/m) mice (SLC, Shizuoka, Japan) and C57BL/6 mice (Orient Bio, Seongnam, Gyeonggi-do, Korea) for in vivo experiments. The control group was fed standard rodent chow (PMI LabDiet; Purina Mills, St Louis, MO, USA) and the rosiglitazone-treated group was fed a mixture of standard chow and rosiglitazone maleate (GlaxoSmithKline, Brentford, UK). From Oxygen consumption rate To determine cellular oxygen consumption in fully differentiated 3T3-L1 adipocytes, the Seahorse Extracellular Flux Analyzer XF24 (Seahorse Bioscience, Billerica, MA, USA) was used [23, 24] .
Bnip3 promoter reporter assays The −2,874 putative peroxisome proliferator hormone responsive element (PPRE) and mutated form of PPRE were introduced into the pGL2P vector in triple repeated form (pGL2P-Bnip3-PPREwt and pGL2P-Bnip3-PPREmt, respectively). 
Results
BNIP3 expression is actively regulated in relation to change of mitochondrial bioenergetics As BNIP3 is known to induce apoptosis/autophagy through mitochondrion-related signalling, we evaluated the expression pattern of BNIP3 under conditions of active mitochondrial turnover. The gene Bnip3 was upregulated from day 2 after differentiation induction and peaked at day 4 in 3T3-L1 adipocytes ( Fig. 1a-d) . The BNIP3 expression pattern closely followed the PPARγ expression pattern (Fig. 1c) . The level of BNIP3 was markedly upregulated in the adipose tissue after starvation (Fig. 1e, f) , in brown adipose tissue (BAT; interscapular fat) (Fig. 1g, h ) and by rosiglitazone treatment (Fig. 1i, j) in vivo. More specifically, Bnip3 upregulation by rosiglitazone occurred mainly in the adipocyte fraction and not in the SVF (containing preadipocytes, macrophages and endothelial cells) (Fig. 1k) . We also evaluated the pattern of BNIP3 expression in adipose tissue from mouse models of obesity. The protein level of BNIP3 was reduced in DIO (Fig. 1l, m) and db/db mice (Fig. 1n , o) compared with control mice. Reduced BNIP3 in the adipose tissue of db/db mice occurred in adipocytes, but not in macrophages in the SVF (Fig. 1p) . Additionally, BNIP3 was strongly downregulated in TNF-α-treated adipocytes compared with vehicle-treated cells in vitro (Fig. 1q, r) . Overall, these findings show a considerable amount of BNIP3 is present in adipocytes and actively regulated by various stimuli related to mitochondrial bioenergetics.
BNIP3 downregulation is restored by a PPARγ agonist in adipocytes in the obese diabetic condition We examined whether rosiglitazone treatment could restore the BNIP3 decrement in db/db mice. After 4 weeks of rosiglitazone treatment, the BNIP3 level in db/db mice increased comparably with that of the rosiglitazone-treated db/m mice ( Fig. 2a, b) . Restoration of BNIP3 expression by rosiglitazone treatment in db/db mice was primarily confined to the cytoplasm of adipocytes (Fig. 2c ). In addition, BNIP3 levels were lower in whole adipose tissue and in the adipocyte fraction in tissue from db/db mice compared with db/m mice, with levels increased by rosiglitazone treatment (Fig. 2d , e). Rosiglitazone treatment also restored the TNF-α-induced BNIP3 decrease in 3T3-L1 adipocytes (Fig. 2f, g ). Next, we evaluated the amount of BNIP3 in the mitochondrial fraction after dividing the lysates from whole adipose tissue in mice and from 3T3-L1 adipocytes into cytosolic and mitochondrial proteins. The expression of BNIP3 per equal amount of mitochondrial protein increased with rosiglitazone treatment both in vivo ( Fig. 2h ) and in vitro (Fig. 2i ).
BNIP3 is a critical molecule for enhancing rosiglitazoneinduced mitochondrial bioenergetics Next, we investigated the role of BNIP3 in 3T3-L1 adipocytes, especially in rosiglitazone-induced adipocyte remodelling in vitro. Using FACS analysis after tagging mitochondria with MitoTracker, we observed that rosiglitazone treatment increased mitochondrial mass in control adipocytes, in contrast to little increase in adipocytes treated with rosiglitazone after BNIP3 knockdown (Fig. 3a) . Additionally, rosiglitazone increased relative mtDNA copy number and Tfam and Nrf1 mRNA levels, all of which were attenuated in BNIP3-knockdown adipocytes exposed to rosiglitazone ( Fig. 3b-d) . However, there were no significant differences in the above variables between the BNIP3-knockdown and the control adipocytes without rosiglitazone treatment. Rosiglitazone also increased ATP content in non-specific scramble small interfering (si)RNA (siNS)-transfected adipocytes, whereas it could not in siBnip3-transfected adipocytes (Fig. 3e) . In TEM images, the number of small dense mitochondria was increased by rosiglitazone treatment in siNS-transfected adipocytes. However, siBnip3-transfected adipocytes showed a heterogeneous mix of small and elongated mitochondria after rosiglitazone treatment (Fig. 3f) . Additionally, BNIP3 knockdown significantly attenuated the rosiglitazone-induced upregulation of the maximal respiration rate. Also, BNIP3 knockdown tended to reduce the increase in energy expenditure (the difference in oxygen consumption rate [OCR] with oligomycin and rotenone) stimulated by rosiglitazone exposure (Fig. 3g, h ). The increase in the mRNA level of Ucp1 on rosiglitazone exposure that was seen in control cells was not apparent in cells with BNIP3 knockdown (Fig. 3i ). This indicates that BNIP3 could be a critical molecule for controlling mitochondrial bioenergetics during rosiglitazone-induced mitochondrial remodelling.
BNIP3 contributes to mitochondrial bioenergetics by activation of the 5′ AMP-activated protein kinase-peroxisome proliferator-activated receptor γ co-activator 1 α pathway, but not by autophagy induction We evaluated whether BNIP3 contributes to mitochondrial bioenergetics in PPARγ agonist-treated 3T3-L1 adipocytes via autophagy activation in vitro. Contrary to expectations, rosiglitazone treatment decreased autophagy, as shown by a decrease in LC3BII and an increase in p62 expression compared with vehicle-treated adipocytes. In TNF-α-treated adipocytes where basal autophagy activity was elevated, rosiglitazone treatment also decreased autophagy (Fig. 4a, left panel) . Additionally, hypoxia upregulated BNIP3 expression to a level comparable with that achieved with rosiglitazone treatment. Rosiglitazone treatment decreased autophagy even after BNIP3 upregulation under hypoxia, a phenomenon similar in cells treated with TNF-α under hypoxia (Fig. 4a, right panel) . The 3T3-L1 adipocytes showed no significant change in LC3B after siBnip3 transfection, and LC3BII was decreased by rosiglitazone treatment independent of BNIP3 knockdown (Fig. 4b) . These findings suggest that upregulation of BNIP3 by rosiglitazone might not induce autophagy, at least not in 3T3-L1 adipocytes.
To clarify how BNIP3 contributes to rosiglitazoneinduced mitochondrial biogenesis, we evaluated the expression of Pgc1α (also known as Ppargc1a), which encodes peroxisome proliferator-activated receptor γ coactivator 1 α and is the master gene regulating mitochondrial biogenesis. Production of PGC1α was upregulated by rosiglitazone treatment, but this effect was attenuated by BNIP3 knockdown, suggesting that BNIP3 is critical in rosiglitazone-induced PGC1α upregulation (Fig. 4c-e) . We also investigated whether rosiglitazone-induced activation of 5′ AMP-activated protein kinase (AMPK), the upstream regulator of PGC1α, depends on BNIP3. Phosphorylation of AMPK by rosiglitazone was attenuated in siBnip3-transfected adipocytes, concordant with the attenuation of adiponectin expression by BNIP3 knockdown even after rosiglitazone stimulation (Fig. 4f-h ). These data suggest that BNIP3 mediates rosiglitazone-induced mitochondrial biogenesis, probably through the AMPK-PGC1α pathway. Direct binding of PPARγ agonist to PPRE in its promoter upregulates Bnip3 transcription Next, we evaluated the mechanism of BNIP3 upregulation by rosiglitazone in vitro. There were minimal changes in Hif1-α (also known as Hif1a) transcription during rosiglitazone-induced BNIP3 upregulation (Fig. 5a, b) . Transcription of Bnip3 significantly increased by twofold after 24 h of rosiglitazone treatment in differentiated 3T3-L1 adipocytes (Fig. 5c, d ). Upregulation of Bnip3 by rosiglitazone diminished in adipocytes transfected with siPparγ (also known as Pparg) (Fig. 5e) , indicating that Bnip3 mRNA expression depends on PPARγ activity. When the PPRE activity was tested in the site from −2,874 to −2,861 bp in the Bnip3 promoter, which exhibited the greatest homology to the consensus PPRE sequence (Fig. 5f) , the −2,874 site showed an approximately twofold increase in reporter luciferase activity with rosiglitazone treatment, whereas the mutant sequence of this site did not (Fig. 5g, h ). In the binding affinity assay, the probe from −2,874 to −2,861 bp in the Bnip3 promoter bound to the same site as the consensus PPRE probe (Fig. 5i) . In the competition assay, binding of the putative PPRE to the radiolabelled probe competed with the unlabelled self-competitors and the control consensus PPRE, but not with the mutant competitors, in a dose-dependent manner. Supershift resulting from the addition of PPARγ-specific antibody further proved that the −2,874 to −2,861 bp region of the Bnip3 promoter is a PPARγ binding site (Fig. 5j) . Together, these results indicate that BNIP3 is transcriptionally upregulated by the PPRE site in the Bnip3 promoter.
Discussion
In this study, we demonstrated that BNIP3 is a critical molecule for controlling mitochondrial bioenergetics in adipocytes. The level of BNIP3 was downregulated in adipocytes under diabetic obese conditions, but was restored by rosiglitazone treatment. Under adipocyte remodelling conditions, BNIP3 determined the fate of mitochondrial bioenergetics, probably by AMPK-PGC1α signalling. Signalling via BNIP3 was directly mediated by the PPRE in the Bnip3 promoter. These findings suggest a critical new role for BNIP3 in the regulation of adipocyte remodelling, especially in the control of mitochondria. Regulation of BNIP3 during adipocyte remodelling, especially in obesity or PPARγ-related conditions The role of BNIP3 has been mostly investigated in myocytes in relation to hypoxia-induced apoptotic cell death and autophagic cell survival [14] . Here, we revealed that a considerable amount of BNIP3 expression is regulated in adipocytes under conditions in which higher mitochondrial content is required, including adipocyte differentiation [10] , starvation [25] and in BAT [26] , and also by rosiglitazone treatment [2, 7, 10] . We also found that BNIP3 was downregulated in adipose tissue under obese diabetic conditions. Our findings that adipocytes with BNIP3 knockdown had attenuated mitochondrial biogenesis and ATP production, even after rosiglitazone treatment (Fig. 3) , suggest that the BNIP3 decrement in obesity might be critical in the deterioration of adipocyte function through mitochondrial dysregulation. The role of BNIP3 during rosiglitazone-induced adipocyte remodelling was of significant interest in this study. We observed that the level of BNIP3 was lower under conditions associated with insulin resistance and was restored by rosiglitazone, a drug known to induce mitochondrial biogenesis [2, 7, 10] . We also found that BNIP3 expression increased primarily in newly developing multilocular adipocytes rather than dying adipocytes in rosiglitazone-treated db/db mice (Fig. 2c) [27, 28] . Therefore, BNIP3 might be involved in rosiglitazone-induced adipocyte remodelling rather than adipocyte death during the change in mitochondrial bioenergetics. The scale of BNIP upregulation in starvation was another interesting point. Even though we could not suggest the exact mechanism, we cautiously speculate that BNIP3 may play a role in maintaining the cellular ATP level and cell survival in the energy-deprived state caused by starvation [29] . Further investigation of this will be necessary.
Adipocyte-specific role of BNIP3 in enhancement of mitochondrial bioenergetics Originally, BNIP3 was reported to impair mitochondrial bioenergetics, as there were defects in mtDNA and ATP production in myocytes [30, 31] . However, our data show that BNIP3 enhances mitochondrial bioenergetics during rosiglitazone treatment, at least in adipocytes. Besides the increase in the amount of mitochondria, it was interesting to note that there was an increase in oxygen consumption and uncoupling, which suggests that BNIP3 enhances mitochondrial function in the adipocytes. The critical differences in the effect of BNIP3 in various tissues might be because of differences in the tissue-specific expression and function of PPARγ [32] [33] [34] , PPARγ coregulators [35, 36] and BNIP3-interacting proteins [37] [38] [39] . In fact, our preliminary experiments using C2C12 myotubes showed the increment in mtDNA copy number resulting from rosiglitazone exposure to be independent of BNIP3 (data not shown). Also, different PPARγ co-regulators might enable BNIP3 to act in a tissue-specific manner [35, 36] . Furthermore, from our bioinformatics analysis, we could find several mitochondria-related proteins that physically interact with BNIP3 [37] [38] [39] and are expressed differently depending on the type of tissue. These findings support our data showing a cell-context-dependent BNIP3 action and explain why the BNIP3-AMPK-PGC1 pathway acts differently in adipocytes in mitochondrial biogenesis.
We have also demonstrated that BNIP3 acts in a favourable way towards mitochondria activity rather than reducing it, at least in adipocytes. This adipocyte-specific action of BNIP3 is very interesting from an evolutionary viewpoint of energy regulation. Unlike BAT, which dissipates energy to produce heat, WAT stores energy. Recently, it has been shown that beige adipocytes sporadically reside with white adipocytes and emerge in response to certain environmental cues, such as chronic cold exposure, a process often referred to as 'browning' of WAT [40] . These findings suggest that beige fat in WAT and its energy dissipation function diminish during the evolution of thermogenic function. Therefore, our finding that BNIP3 plays an important role in enhancing mitochondria bioenergetics after PPARγ agonist stimulation could contribute to our understanding of the molecular mechanism of 'browning'.
Downstream pathway of BNIP3 in controlling mitochondrial remodelling Previously, BNIP3 has been shown to induce autophagy on exposure to rosiglitazone [41, 42] . However, we could not find any evidence of autophagy activation by BNIP3 in adipocytes. Rather, rosiglitazone exposure decreased autophagy, even after BNIP3 upregulation (Fig. 4a, b) . Therefore, BNIP3-mediated signalling in adipocytes might not act on autophagy regulation but may have a more intricate role during adipocyte remodelling. Here, it was interesting to find a possible role of PGC1α, a master transcription co-activator for mitochondrial biogenesis [43, 44] , as a downstream molecule involved in PPARγ-agonist-induced BNIP3 signalling in adipocytes. In our experiment, adiponectin was upregulated by rosiglitazone in a BNIP3-dependent manner. It is known that adiponectin can activate the AMPK-PGC1α pathway, resulting in mitochondrial biogenesis [45] . Even though we could not definitively propose how BNIP3 mediates PGC1α upregulation by rosiglitazone, we propose that adiponectin-AMPK is one of the axes responsible. Considering that mitochondrial function is essential for adiponectin synthesis in adipocytes [46] , BNIP3 might be a checkpoint for mitochondrial quality control [47] and the AMPK-PGC1α mitochondrial bioenergetics pathway through which rosiglitazone acts. Further investigation of the precise mechanism of BNIP3-mediated mitochondrial biogenesis is warranted.
BNIP3 regulation by a PPARγ agonist in adipocytes So far, the regulation of BNIP3 expression has been focused on hypoxia inducible factor 1, α subunit (basic helix-loop-helix transcription factor) (HIF-1α), a well-known transcription factor activated by hypoxia [16] . It is known that HIF-1α upregulates BNIP3 and that the upregulated BNIP3 consequently activates autophagy, probably for survival against hypoxic stress [48] . Another molecule associated with BNIP3 regulation may be a PPARγ agonist, regardless of the increase in HIF-1α or autophagy [49] . In our study, we found that Bnip3 transcription is upregulated by a PPARγ agonist in adipocytes, irrespective of HIF-1α (Fig. 5a, b) . This is supported by the pattern of BNIP3 expression resembling that of PPARγ expression (Fig. 1c) .
In conclusion, we propose a novel role for BNIP3 in mitochondrial bioenergetics in remodelling adipocytes and reveal a cell-context-dependent action of BNIP3 unique from that of other cells. The impairment in BNIP3 function in adipocytes might act to cause the mitochondrial bioenergetics to deteriorate and our finding suggests that a cell-type-specific measure to control BNIP3 may be a potential therapeutic target in obesity.
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